Mylan Ireland Ltd Drug Patent Portfolio
Mylan Ireland Ltd owns 1 orange book drug protected by 21 US patents Given below is the list of Mylan Ireland Ltd's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11484531 | Methods for treating chronic obstructive pulmonary disease | 23 Oct, 2039 | Active |
| US12048692 | Methods for treating chronic obstructive pulmonary disease | 29 Aug, 2039 | Active |
| US12285417 | Methods for treating chronic obstructive pulmonary disease | 29 Aug, 2039 | Active |
| US8541451 | Crystalline freebase forms of a biphenyl compound | 25 Aug, 2031 | Active |
| US10550081 | Crystalline freebase forms of a biphenyl compound | 14 Jul, 2030 | Active |
| US11008289 | Crystalline freebase forms of a biphenyl compound | 14 Jul, 2030 | Active |
| US11691948 | Crystalline freebase forms of a biphenyl compound | 14 Jul, 2030 | Active |
| US11858898 | Crystalline freebase forms of a biphenyl compound | 14 Jul, 2030 | Active |
| US9765028 | Crystalline freebase forms of a biphenyl compound | 14 Jul, 2030 | Active |
| US7288657 | Biphenyl compounds useful as muscarinic receptor antagonists | 31 Oct, 2028 | Active |
| US10106503 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Expired |
| US10343995 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Expired |
| US11247969 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Expired |
| US7491736 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Expired |
| US7521041 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Expired |
| US7550595 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Expired |
| US7585879 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Expired |
| US7910608 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Expired |
| US8034946 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Expired |
| US8053448 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Expired |
| US8273894 | Biphenyl compounds useful as muscarinic receptor antagonists | 10 Mar, 2025 | Expired |
Latest Legal Activities on Mylan Ireland Ltd's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Mylan Ireland Ltd.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 03 May, 2024 | US7585879 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 03 May, 2024 | US7585879 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 25 Apr, 2024 | US7288657 |
|
Email Notification
Critical
| 25 Apr, 2024 | US7288657 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 25 Mar, 2024 | US8273894 |
| Notice of Final Determination -Election Required | 22 Mar, 2024 | US7288657 |
| Notice of Final Determination -Election Required | 22 Mar, 2024 | US7585879 |
|
Email Notification
Critical
| 20 Feb, 2024 | US11858898 |
| Mail Patent eCofC Notification | 20 Feb, 2024 | US11858898 |
| Patent eCofC Notification | 20 Feb, 2024 | US11858898 |
| Recordation of Patent eCertificate of Correction | 20 Feb, 2024 | US11858898 |
| Post Issue Communication - Certificate of Correction | 31 Jan, 2024 | US11858898 |
| Mail Patent eGrant Notification | 02 Jan, 2024 | US11858898 |
| Patent eGrant Notification | 02 Jan, 2024 | US11858898 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 02 Jan, 2024 | US11858898 |
Mylan Ireland Ltd's Family Patents
Mylan Ireland Ltd drugs have patent protection in a total of 31 countries. It's US patent count contributes only to 39.8% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Recent FDA approvals and tentative approvals for Mylan Ireland Ltd
This section lists recent FDA approvals and tentative approvals for Lupin, covering innovator and generic drugs with key regulatory details and timelines.
Innovator drugs
Includes innovator drug submissions that appear in FDA approval and tentative approval disclosures.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Efavirenz, Emtricitabine And Tenofovir Alafenamide |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 4 - New Combination | 22 Mar, 2024 |
| Darunavir And Ritonavir |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 4 - New Combination | 22 Dec, 2023 |
| Dolutegravir, Lamivudine, And Tenofovir Disoproxil Fumarate |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | Type 4 - New Combination | 02 Aug, 2017 |
Generic drugs
Includes generic drug submissions with tentative FDA approvals, not yet marketable due to patent or exclusivity restrictions.
| Drug Name | Submission class (FDA) | Submission Category | Submission Date |
|---|---|---|---|
| Aprepitant |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 17 Nov, 2025 |
| Paliperidone Palmitate |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 03 Dec, 2024 |
| Sugammadex |
ORIG-1
ⓘ
Orig = Original submission Suppl = Supplement submission Number = submission sequence | - | 20 Nov, 2024 |
Mylan Ireland Ltd Drug List
Given below is the complete list of Mylan Ireland Ltd's drugs and the patents protecting them.
1. Yupelri
Yupelri is protected by 21 patents, out of which 11 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11484531 | Methods for treating chronic obstructive pulmonary disease |
23 Oct, 2039
(13 years from now)
| Active |
| US12048692 | Methods for treating chronic obstructive pulmonary disease |
29 Aug, 2039
(13 years from now)
| Active |
| US12285417 | Methods for treating chronic obstructive pulmonary disease |
29 Aug, 2039
(13 years from now)
| Active |
| US8541451 | Crystalline freebase forms of a biphenyl compound |
25 Aug, 2031
(5 years from now)
| Active |
| US10550081 | Crystalline freebase forms of a biphenyl compound |
14 Jul, 2030
(4 years from now)
| Active |
| US11008289 | Crystalline freebase forms of a biphenyl compound |
14 Jul, 2030
(4 years from now)
| Active |
| US11691948 | Crystalline freebase forms of a biphenyl compound |
14 Jul, 2030
(4 years from now)
| Active |
| US11858898 | Crystalline freebase forms of a biphenyl compound |
14 Jul, 2030
(4 years from now)
| Active |
| US9765028 | Crystalline freebase forms of a biphenyl compound |
14 Jul, 2030
(4 years from now)
| Active |
| US7288657 | Biphenyl compounds useful as muscarinic receptor antagonists |
31 Oct, 2028
(2 years from now)
| Active |
| US10106503 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(9 months ago)
| Expired |
| US10343995 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(9 months ago)
| Expired |
| US11247969 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(9 months ago)
| Expired |
| US7491736 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(9 months ago)
| Expired |
| US7521041 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(9 months ago)
| Expired |
| US7550595 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(9 months ago)
| Expired |
| US7585879 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(9 months ago)
| Expired |
| US7910608 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(9 months ago)
| Expired |
| US8034946 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(9 months ago)
| Expired |
| US8053448 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(9 months ago)
| Expired |
| US8273894 | Biphenyl compounds useful as muscarinic receptor antagonists |
10 Mar, 2025
(9 months ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Yupelri's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List